All In Biotech

Drug Trial Radar · NCT05506540

A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects

A Phase 1, First-in-human, 2-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Single Ascending Dose and Multiple Ascending Dose (SAD/MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ENN0403 in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

69

Actual

Start

Feb 17, 2021

Primary completion

May 16, 2022

Study completion May 16, 2022

Sponsor

Lead sponsor
EnnovaBioIndustry
Sponsor type
Industry
First posted
Aug 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a FIH, randomized, double- blind, placebo-controlled, dose -escalation study to investigate the safety, tolerability, PK, and PD of ENN0403 after single and multiple oral dose administration in healthy adult subjects. The study will include 2 parts which will proceed in a parallel staggered manner: Part A, a single ascending dose (SAD) study and Part B, a multiple ascending dose (MAD) study. Approximately 80 healthy adult subjects will be enrolled at a single site in Australia, in up to 6 cohorts in Part A (SAD study), including a Food Effect (FE) study, and up to 4 cohorts in Part B (MAD study). Part A is for the single dose use of IP, while Part B is once daily use for 14 consecutive days. Each cohort will include 8 subjects (6 receiving ENN0403 and 2 receiving placebo). Each subject will be enrolled in only 1 cohort and receive only one dose regimen in this study. Dosing will be escalated in a sequential fashion, contingent on a review of safety, tolerability, and available PK data of the previous dose level by a Safety Review Committee (SRC). The proposed dose levels/ dosing frequency of ENN0403 may be adjusted over the course of the whole study and cohorts may be added or removed depending on the emerging safety, tolerability, and available PK data.

Conditions

  • Healthy

Interventions

  • ENN0403 1mgDrug

    ENN0403 capsules for oral use

  • ENN0403 4mgDrug

    ENN0403 capsules for oral use

  • ENN0403 10mgDrug

    ENN0403 capsules for oral use

  • ENN0403 20mgDrug

    ENN0403 capsules for oral use

  • ENN0403 30mgDrug

    ENN0403 capsules for oral use

  • ENN0403 20mg (Fed)Drug

    ENN0403 capsules for oral use

  • ENN0403 6mg QD X 14 DaysDrug

    ENN0403 capsules for oral use

  • ENN0403 12mg QD X 14 DaysDrug

    ENN0403 capsules for oral use

  • ENN0403 20mg QD X 14 DaysDrug

    ENN0403 capsules for oral use

  • PlaceboDrug

    Placebo capsules for oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment emergent adverse events (TEAE) following ENN0403 administrationTime frame: From first dose of ENN0403 administration till 7 days after last dose of ENN0403 administration.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research Pty Ltd

    Adelaide, Adelaide, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.